University of Minnesota
University Relations
myU OneStop

Go to unit's home.

Home | Seminars and Symposia | Past seminars/symposia: Friday, November 7, 2008

Differential transcriptomics for the prognosis and sub-typing of cancer


George Vasmatzis
Senior Associate Consultant
Mayo Clinic Cancer Center

Friday, November 7, 2008
12:00 lunch 401 Walter,
cookies in 322 UMR
12:15 seminar 402 Walter (remote)

322 UMR

Note: this seminar will be presented from room 322 at the University of Minnesota Rochester (UMR) and will be available for viewing in room 402 Walter Library. Interested Rochester area researchers are invited to attend the seminar at UMR.

Management of an individual's cancer depends on accurately determining the subtype and progression state of his tumor and predicting short and long-term outcome of the patient's disease following prescribed therapeutic interventions. For example, current clinicopathological evaluation of prostate cancer patients cannot accurately predict systemic progression following Radical Retropubic Prostatectomy (RRP). This is particularly true for patients with intermediate and high Gleason scores (GS≥7), who comprise nearly 35% of the prostate cancer patients that undergo RRP at Mayo Clinic. For this group of patients, the systemic progression rate is close to 13%. Stratification of these patients based on the likelihood of systemic progression and death due to prostate cancer is a key prerequisite for a more individualized approach to therapy. We have recently shown that a simple multi-variable model using molecular markers can significantly improve the predictive accuracy of clinic al and pathologic variables (0.8 AUC in ROC analysis) when applied specifically to the GS≥7 patient population in a case-control setting where all clinically available prognostic measures including extra-capsular extension, nodal invasion, and adjuvant therapy were either matched or balanced (see Cheville et. al. JCO 2008). Our predictive model included 3 molecular parameters, namely TOP2A, CDH10 and the TMPRSS2-ETS-family fusion status. Since the TMPRSS2-ETS fusion appears to be an early event in carcinogenesis of prostate cancer (Perner et al., 2007), our data as well as recent reports (Tomlins et al., 2008) raise the possibility that this fusion leads to a distinct molecular subtype.


Dr. George Vasmatzis is a Senior Associate Consultant in the Experimental Pathology division, in the Department of Laboratory Medicine and Pathology and a member of the Mayo Clinic Cancer Center. He is also an Assistant Professor in the Department of Laboratory Medicine at the Mayo Medical School. He has a Ph.D. in Biomedical Engineering and has acquired experience in diverse disciplines, including Bioinformatics, Molecular Biology, and Computational Biology.